Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
Kelun-Biotech received Investigational New Drug (IND) approval from the NMPA in China for SKB105, an ITGB6-targeted ADC, for the treatment of advanced solid tumors.
Kelun-Biotech received Breakthrough Therapy Designation (BTD) in China for sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab for first-line treatment of PD-L1-positive, EGFR-negative, ALK-negative NSCLC.
